Indicators
Indicators
Value
Direction
MACD(12,26,9)
-0.015
Neutral
RSI(14)
49.568
Neutral
STOCH(KDJ)(9,3,3)
26.048
Neutral
ATR(14)
0.110
High Vlolatility
CCI(14)
-37.112
Neutral
Williams %R
73.333
Sell
TRIX(12,20)
0.203
Sell
StochRSI(14)
0.000
Sell
Search
ProQR Therapeutics NV
PRQRAdd to Watchlist
1.720USD
-0.060-3.37%
Close 07-31 16:00（ET）Quotes delayed by 15 min
228.74MMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey ChartIntraday
1m
30m
1h
D
W
M
D
Today
-3.37%
5 Days
0.00%
1 Month
-1.71%
6 Months
+6.17%
Year to Date
-14.85%
1 Year
-17.31%
Key Figures
1.790Open
1.790High
1.02MVolume
LossP/E TTM
LossP/E Dynamic
--Dividend TTM
0.94%Turnover Ratio
1.780Prev. Close
1.700Low
911.98KTurnover
LossP/E Static
4.20P/B
0.00%Div Yield TTM
-36.29%ROA
3.10052wk High
1.63Volume Ratio
-27.76MNet Profit
107.71MShares
-0.3738EPS TTM
0.07Beta
-78.07%ROE
1.33052wk Low
5.06%Amplitude
100.00%Gross Margin
228.74MMarket Cap
0.74Reward/Risk
4.71%Risk Rate
TradingKey Stock Score of ProQR Therapeutics NV
Currency: USD Updated: 2026-07-31Key Insights
ProQR Therapeutics NV's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 148 out of 385 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 9.00.In the medium term, the stock price is expected to remain stable.Despite an average stock market performance over the past month, the company shows strong fundamentals.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
ProQR Therapeutics NV's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive+
ProQR Therapeutics NV Highlights
StrengthsRisks
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 116.22% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 18.82M.
High Profit Growth
The company's net income leads the industry, with the latest annual income totaling USD 18.82M.
Overvalued
The company’s latest PE is -4.60, at a high 3-year percentile range.
Institutional Selling
The latest institutional holdings are 38.34M shares, decreasing 12.89% quarter-over-quarter.
Held by Steven Cohen
Star Investor Steven Cohen holds 782.05K shares of this stock.
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+420.23%
Upside Space
ProQR Therapeutics NV News
More news coming soon, stay tuned...
Earnings Forecast
Analyst Rating
Based on
9
analysts
Buy
Current Rating
9.000
Target Price
+420.23%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
496
Total
6
Median
7
Average
Company name
Ratings
Analysts
ProQR Therapeutics NV
PRQR
9
Beigene Ltd
ONC
28
argenx SE
ARGX
26
Ionis Pharmaceuticals Inc
IONS
26
IQVIA Holdings Inc
IQV
25
Insmed Inc
INSM
23
1
2
3
...
99
Indicators
Moving Average
Indicators
Value
Direction
MA5
1.744
Sell
MA10
1.768
Sell
MA20
1.739
Sell
MA50
1.655
Buy
MA100
1.666
Buy
MA200
1.845
Sell
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
ProQR Therapeutics NV Info
ProQR Therapeutics N.V. is a biotechnology company based in the Netherlands. The Company is engaged in the discovery and development of ribonucleic Acid (RNA)-based therapeutics for the treatment of severe genetic disorders. Main purpose of the Company is advancement of its Axiomer RNA-editing platform technology. That technology uses a cell’s own editing machinery called ADAR to make specific single nucleotide edits in RNA to reverse a mutation or modulate protein expression and could potentially yield a new class of medicines for both rare and prevalent diseases with unaddressed needs. The Company operates research pipeline that contains of RNA Therapy and AX-0810 Cholestatic Diseases (NTCP).
Ticker SymbolPRQR
CompanyProQR Therapeutics NV
CEOde Boer (Daniel Anton)
Websitehttps://www.proqr.com/
Shareholders
Related Instruments
-0.53%
+0.27%
-2.51%
+0.32%
-1.45%
-0.92%
-0.64%
-0.82%
-8.79%
+0.52%
+0.68%
-0.95%
-0.71%
+0.44%
-1.08%
+3.29%
0.00%
-0.90%
+1.30%
-2.15%Popular Instruments
52378.000
+109.000 (+0.21%)
28160.900
-37.600 (-0.13%)
7475.100
+30.800 (+0.41%)
14749.000
-90.000 (-0.61%)
62852.000
-742.000 (-1.17%)
6365.400
-1.000 (-0.02%)
85.934
+2.764 (+3.32%)
308.910
-24.520 (-7.35%)
200.750
+5.710 (+2.93%)
4041.430
-61.400 (-1.50%)
FAQs
What is the current price of ProQR Therapeutics NV (PRQR)?
The current price of ProQR Therapeutics NV (PRQR) is 1.72.
What is the symbol of ProQR Therapeutics NV?
The ticker symbol of ProQR Therapeutics NV is PRQR.
What is the 52-week high of ProQR Therapeutics NV?
The 52-week high of ProQR Therapeutics NV is 3.10.
What is the 52-week low of ProQR Therapeutics NV?
The 52-week low of ProQR Therapeutics NV is 1.33.
What is the market capitalization of ProQR Therapeutics NV?
The market capitalization of ProQR Therapeutics NV is 185.26M.
Is ProQR Therapeutics NV (PRQR) currently rated as Buy, Hold, or Sell?
According to analysts, ProQR Therapeutics NV (PRQR) has an overall rating of Buy, with a price target of 9.00.
What is the Earnings Per Share (EPS TTM) of ProQR Therapeutics NV (PRQR)?
The Earnings Per Share (EPS TTM) of ProQR Therapeutics NV (PRQR) is -0.47.